Relevance of COMT inhibitors in the treatment of motor fluctuations

被引：0

作者：

Jost, Wolfgang H. ^{[1
]}

Buhmann, Carsten ^{[2
]}

Classen, Joseph ^{[3
]}

Eggert, Karla ^{[4
]}

Kohl, Zacharias ^{[5
]}

Outeiro, Tiago ^{[6
]}

Tonges, Lars ^{[7
]}

Woitalla, Dirk ^{[8
]}

Reichmann, Heinz ^{[9
]}

机构：

[1] Parkinson Klin Ortenau, Wolfach, Germany

[2] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Neurol, Hamburg Eppendorf, Germany

[3] Univ Klinikum Leipzig, Klin & Poliklin Neurol, Leipzig, Germany

[4] Univ Marburg, Klin Neurol, Marburg, Germany

[5] Univ Regensburg, Klin & Poliklin Neurol, Regensburg, Germany

[6] Univ Med Gottingen, Expt Neurodegenerat, Gottingen, Germany

[7] Ruhr Univ Bochum, Klinikum Ruhr Univ Bochum, Neurol Klin, St Josef Hosp, Bochum, Germany

[8] St Josefs Hosp, Klin Neurol, Essen Kupferdreh, Germany

[9] Univ Klinikum Carl Gustav Carus Dresden, Klin & Poliklin Neurol, Dresden, Germany

来源：

NERVENARZT | 2022年 / 93卷 / 10期

关键词：

Parkinson's disease; Motor fluctuations; Entacapone; Opicapone; Tolcapone; PARKINSONS-DISEASE PATIENTS; WEARING-OFF; LEVODOPA; OPICAPONE; ENTACAPONE; LEVODOPA/CARBIDOPA; COMPLICATIONS; EFFICACY; THERAPY; PHARMACOKINETICS;

D O I：

10.1007/s00115-021-01237-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Catechol O-methyltransferase (COMT) inhibitors have been established in the treatment of Parkinson's disease for more than 20 years. They are considered the medication of choice for treating motor fluctuations. The available COMT inhibitors, entacapone, opicapone and tolcapone, differ pharmacokinetically in terms of their half-lives with implications for the dose frequency, in their indication requirements and in their spectrum of side effects, including diarrhea and yellow discoloration of urine. Many patients with motor fluctuations are currently not treated with COMT inhibitors and are, therefore, unlikely to receive individually optimized drug treatment. This manuscript summarizes the results of a working group including several Parkinson's disease experts, in which the value of COMT inhibitors was critically discussed.

引用

页码：1035 / 1045

页数：11

共 60 条

[1]

[Anonymous], EUROPEAN HDB NEUROLO

[2]

[Anonymous], 2006, PARK DIS 20S DIAGN M

[3]

Antonini A, 2020, PARKINSONISM RELAT D, V79, pE64

[4] Clinical Spectrum of Levodopa-Induced Complications [J].

Aquino, Camila Catherine ;

Fox, Susan H. .

MOVEMENT DISORDERS, 2015, 30 (01) :80-89

[5] Diagnosis and Treatment of Parkinson Disease A Review [J].

Armstrong, Melissa J. ;

Okun, Michael S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (06) :548-560

[6]

AWMF, 2016, S3 LEITL ID PARK SYN

[7] Major Nutritional Issues in the Management of Parkinson's Disease [J].

Barichella, Michela ;

Cereda, Emanuele ;

Pezzoli, Gianni .

MOVEMENT DISORDERS, 2009, 24 (13) :1881-1892

[8]

Bial-Portela Ca, 2020, FACH ONG

[9]

Borovac Josip Andelo, 2016, Yale Journal of Biology and Medicine, V89, P37

[10] Pill swallowing in Parkinson's disease: A prospective study based on flexible endoscopic evaluation of swallowing [J].

Buhmann, Carsten ;

Bihler, Moritz ;

Emich, Katharina ;

Hidding, Ute ;

Poetter-Nerger, Monika ;

Gerloff, Christian ;

Niessen, Almut ;

Fluegel, Till ;

Koseki, Jana-Christina ;

Nienstedt, Julie Claere ;

Pflug, Christina .

PARKINSONISM & RELATED DISORDERS, 2019, 62 :51-56

← 1 2 3 4 5 6 →